4/A: CEO Platt Amends Ownership, Acquires Shares in NDPD Sale

BIOXYTRAN CEO David Platt amended his beneficial ownership, acquiring 11.4 million preferred shares as payment for the sale of NDPD to Bioxytran, while 14 million indirect shares were cancelled.

Summary

• David Platt, CEO, Director, and 10% owner of BIOXYTRAN, INC, filed an amendment to his beneficial ownership statement.
• 14,085,410 preferred shares, previously held indirectly through NDPD Pharma, were returned to treasury and cancelled at a price of $0.285 per share.
• The total holdings of BIXT by NDPA Pharma, an affiliate whose beneficial ownership includes David Platt, Ola Soderquist, and Mike Sheikh, were consolidated under indirect ownership in David Platt's filing.
• 11,433,448 preferred shares were directly acquired by David Platt at a price of $0.545 per share.
• These acquired shares were issued as payment for the sale of NDPD to Bioxytran.
• Following these transactions, David Platt's direct beneficial ownership of preferred shares stands at 20,038,903.

Sentiment

Score: 6

Explanation: The filing details a strategic acquisition where Bioxytran issued shares to its CEO as payment for NDPD, suggesting corporate activity and potential growth. The clarification of beneficial ownership is a positive for transparency. However, the cancellation of a large block of shares and the unusual future signature date introduce minor uncertainties.

Positives

• The acquisition of 11,433,448 preferred shares by CEO David Platt as payment for the sale of NDPD to Bioxytran indicates a strategic transaction and potential integration of NDPD's assets or operations into Bioxytran.
• The consolidation of indirect holdings under David Platt's filing provides clearer transparency regarding beneficial ownership.

Negatives

• The cancellation of 14,085,410 preferred shares previously held indirectly through NDPD Pharma, even if a restructuring, represents a reduction in that specific block of shares.
• The signature date of 11/18/2025 is in the future, which is highly unusual for a Form 4/A and could indicate a clerical error or raise questions about the filing's accuracy.

Future Outlook

No explicit future outlook or guidance is provided in this Form 4/A filing, which primarily details insider transactions and ownership changes.

Management Comments

• "The shares were returned to treasury and cancelled."
• "The total holdings of BIXT by NDPA Pharma, an affiliate whose beneficial ownership includes David Platt, Ola Soderquist and Mike Sheikh were consolidated under indirect ownership in David Platt's filing."
• "The shares were issued as payment for the sale of NDPD to Bioxytran."

Industry Context

This filing primarily details insider transactions and ownership restructuring related to an acquisition (NDPD by Bioxytran). It indicates Bioxytran's strategic move to acquire NDPD, but does not provide sufficient information to analyze broader industry trends or competitors directly.

Corporate Governance

Related Party Transactions

• David Platt, CEO of Bioxytran, received 11,433,448 preferred shares as payment for the sale of NDPD to Bioxytran. NDPD Pharma, an affiliate whose beneficial ownership includes David Platt, had its holdings consolidated under David Platt's indirect ownership, indicating a related-party transaction.

Stakeholder Impact

• Shareholders: The acquisition of NDPD could be seen as a strategic move to enhance company value, potentially benefiting shareholders in the long term. The issuance of shares as payment could lead to dilution, but the strategic benefit might outweigh it.
• Management/Insiders: David Platt's direct ownership increased significantly, aligning his interests further with the company's performance.

Key Dates

Recommendation

The filing details a significant insider transaction where the CEO acquired shares as payment for an acquisition. This indicates strategic corporate activity. While the acquisition itself could be positive, the details provided in a Form 4/A are limited to ownership changes. Without more information on the acquired entity (NDPD) and its financial impact on Bioxytran, a 'hold' recommendation is prudent. The unusual future signature date also introduces a minor element of uncertainty.

Keywords

BIOXYTRAN, BIXT, David Platt, SEC Form 4/A, Beneficial Ownership, Preferred Shares, NDPD Pharma, CEO, Insider Trading, Stock Acquisition, Share Cancellation, Corporate Governance